Policy · 4h ago
Telehealth Firms Eye Windfall as FDA Weighs Peptide Rule Change
The FDA may decide this week to relax regulations on peptide production, opening a new market for telehealth companies. These firms are already positioning to capitalize on the potential policy shift. The decision could reshape the landscape for custom peptide therapies.
Meridian48 take
The hype around peptides may outpace the actual regulatory change, but telehealth companies are betting big on a looser FDA stance.
fda-regulationtelehealth